Augmentin Dosing in Dialysis Patients
For patients on hemodialysis, administer Augmentin (amoxicillin/clavulanate) 500/125 mg orally immediately after each dialysis session, typically 3 times per week. Both amoxicillin and clavulanic acid are significantly removed by hemodialysis (approximately 64-65% fractional removal), necessitating post-dialysis dosing to maintain therapeutic concentrations 1, 2.
Key Dosing Principles
Hemodialysis Patients
- Standard dose: 500/125 mg orally after each dialysis session
- Timing is critical: Always administer immediately after dialysis to prevent premature drug removal 1
- Both components are dialyzable with extraction ratios of 0.44 (amoxicillin) and 0.74 (clavulanic acid) 2
- Recent evidence confirms that oral administration 30-120 minutes before dialysis maintains adequate prophylactic concentrations throughout the dialysis period 3
Pharmacokinetic Considerations
The pharmacokinetics are dramatically altered in end-stage renal disease:
- Amoxicillin: Terminal half-life increases from ~1 hour (normal) to 13.6 hours (off-dialysis), dropping to 2.3 hours during dialysis 1
- Clavulanic acid: Terminal half-life increases from ~1 hour (normal) to 3.05 hours (off-dialysis), dropping to 1.19 hours during dialysis 1
- Total serum clearance on non-dialysis days is significantly reduced compared to normal subjects, suggesting some hepatic impairment in ESRD patients 1
Important Caveats
Do not use standard dosing regimens - the FDA label does not provide specific hemodialysis dosing for Augmentin, but pharmacokinetic data clearly demonstrate drug accumulation with standard dosing and significant dialytic removal 4, 1, 2.
Avoid dose reduction strategies - instead of reducing the dose, extend the dosing interval to post-dialysis administration only. This maintains adequate peak concentrations while preventing accumulation 2.
Monitor for adverse effects: Patients with renal insufficiency may experience increased gastrointestinal side effects due to altered drug metabolism, even with adjusted dosing 4.
Peritoneal Dialysis
Data for peritoneal dialysis patients are extremely limited. The FDA label specifically states "use with caution" in this population 4. If Augmentin must be used, consider starting with the hemodialysis dosing regimen (500/125 mg three times weekly) with close clinical monitoring, though this is extrapolated guidance without supporting evidence.
Clinical Monitoring
- Assess hepatic function regularly, as ESRD patients show reduced non-renal clearance 1
- Watch for superinfections, particularly with Candida or Pseudomonas 4
- Monitor for diarrhea (occurs in ~13% of patients) and discontinue if severe or persistent 4
- Consider therapeutic drug monitoring in complex cases, though this is rarely available for amoxicillin/clavulanate in routine practice
Critical pitfall: Do not substitute different Augmentin formulations interchangeably - the clavulanic acid content varies significantly between formulations (e.g., ES-600 contains 42.9 mg/5mL vs. standard 400 mg/5mL suspension contains 57 mg/5mL) 4.